Market Place
Sourcing Support
All News #Library
Biotech
US FDA approves Axsome`s drug for Alzheimer`s-related agitation
02 May 2026 //
REUTERS
Axsome Acquires PDE10A Inhibitor Balipodect for Schizophrenia
01 Apr 2026 //
GLOBENEWSWIRE
Axsome Therapeutics Joins Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Axsome Launches Solriamfetol CLARITY Phase 3 Trial in MDD
24 Feb 2026 //
GLOBENEWSWIRE
Axsome Therapeutics at 36th Oppenheimer Healthcare Conference
18 Feb 2026 //
GLOBENEWSWIRE
Axsome Therapeutics to Report Q4, FY25 Financial Results on Feb
27 Jan 2026 //
GLOBENEWSWIRE
Axsome Starts Phase 3 Trial For AXS-14 In Fibromyalgia Management
15 Jan 2026 //
GLOBENEWSWIRE
Axsome Therapeutics Gets FDA Priority Review For AXS-05
31 Dec 2025 //
GLOBENEWSWIRE
Axsome Therapeutics Reveals FDA Meeting Outcome For AXS-12
31 Dec 2025 //
GLOBENEWSWIRE
Axsome Therapeutics Joins Investor Conferences
20 Nov 2025 //
GLOBENEWSWIRE
Axsome Therapeutics Showcases Neuroscience Pipeline Data
17 Sep 2025 //
GLOBENEWSWIRE
Axsome Backs Migraine Awareness With Patient Advocacy Group
16 Jun 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.